Skip to main content
    B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.50
    +0.05 (+0.67%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 4:51 PM ET

    BioCryst Pharmaceuticals Inc (BCRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    BioCryst Pharmaceuticals (BCRX) has a market cap of $1.96B and an enterprise value of $2.26B. Its return on invested capital of 24937.07% compares with a 7.96% median across 10 similar companies. Its share count is up 21.63% from a year earlier.

    Total Valuation

    Enterprise value is 15.28% above the market cap, as debt exceeds cash.

    Market Cap$1.96B
    Enterprise Value$2.26B
    Latest price (Nov 17, 2026)$7.50

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.45% in the quarter ended Sep 30, 2026 and grew 11.15% a year over 2 years.

    Shares Outstanding255.63M
    Shares Change (YoY)+21.63%
    Shares Change (QoQ)+0.45%
    Share Count Growth (2Y CAGR)+11.15%

    Valuation Ratios

    The price to sales ratio is 2.0x.

    P/E Ratio4.4x
    P/S Ratio2.0x
    Forward P/S2.7x
    P/FCF Ratio5.2x
    P/OCF Ratio5.3x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 6.1x free cash flow.

    EV / Sales2.3x
    EV / FCF6.1x

    Price Statistics

    The stock is up 5.93% over 52 weeks and trades 7.98% below its 50-day average.

    Beta (1Y)0.66
    52-Week Change+5.93%
    1-Month Change-7.06%
    3-Month Change-25.52%
    6-Month Change-14.48%
    5-Year Change-43.27%
    10-Year Change+109.14%
    Total Return (1Y)+5.93%
    Total Return (3Y CAGR)+11.92%
    Total Return (5Y CAGR)-8.59%
    Return vs SPY (1Y)-4.42%
    Max Drawdown (1Y)-32.94%
    Max Drawdown (3Y)-46.01%
    Sharpe Ratio (1Y)0.15
    Correlation with SPY (1Y)0.19
    50-Day Average$8.15
    200-Day Average$8.81
    52-Week Range$6.23 to $11.22
    RSI (14 Days)39.4
    Average Volume (20 Days)5.26M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.71x current liabilities.

    Current Ratio2.71x
    Quick Ratio2.64x
    Debt / FCF1.08x
    Interest Coverage3.67x

    Returns and Efficiency

    Return on invested capital is 24937.07% over the last 12 months.

    Return on Assets (ROA)-60.85%
    Return on Invested Capital (ROIC)24937.07%
    Return on Capital Employed (ROCE)-72.68%
    ROA (5Y Average)-17.37%
    Asset Turnover1.85x
    Inventory Turnover2.05x
    Receivables Turnover8.27x
    Cash Conversion Cycle-12 days

    Scores

    BCRX has an Altman Z-Score of -3.13, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score-3.13
    Altman Z ZoneDistress
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $961.51M over the last 12 months is up 60.30% from the 12 months before.

    Revenue$961.51M
    Revenue Growth (YoY)+60.30%
    Gross Profit$941.20M
    Operating Income-$289.42M
    Pretax Income-$354.73M
    Net Income-$359.66M
    EBITDA-$287.57M
    EBIT-$287.27M
    Reported EPS (TTM)$1.70

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$96.97M
    Total Debt$396.23M
    Net Debt$299.26M
    Net Debt Per Share$1.17
    Working Capital$335.32M
    Shareholder Equity-$397.38M
    Total Assets$591.07M
    Total Liabilities$988.45M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.65M of capital spending, operating cash flow left $365.85M of free cash flow.

    Operating Cash Flow$367.49M
    Capital Expenditures$1.65M
    Free Cash Flow$365.85M
    FCF Per Share$1.43
    Depreciation and Amortization$5.22M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -30.10%, against a 5-year average of -32.15%.

    Gross Margin97.89%
    Operating Margin-30.10%
    Pretax Margin-36.89%
    Net Margin-37.41%
    EBITDA Margin-29.91%
    EBIT Margin-29.88%
    FCF Margin38.05%
    Gross Margin (5Y Average)97.36%
    Operating Margin (5Y Average)-32.15%
    Net Margin (5Y Average)-53.25%

    Growth

    Revenue grew 47.82% a year over 3 years.

    Revenue Growth (3Y CAGR)+47.82%
    Revenue Growth (5Y CAGR)+117.89%

    Revenue and profit by year

    Dividends and Yields

    BCRX does not pay a dividend. Its free cash flow yield is 19.08%.

    Earnings Yield22.73%
    FCF Yield19.08%
    Buyback Yield-1.59%
    Shareholder Yield-1.59%

    Peer Position

    Against 12 similar companies, BCRX has the 11th highest P/E and the 6th highest P/S.

    P/E Ratio4.4x vs 10.7x median
    P/S Ratio2.0x vs 2.0x median
    ROIC24937.07% vs 7.96% median
    Revenue Growth (Trailing 4 Quarters, YoY)+60.30% vs +10.45% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -8.27% and EPS growth at -19.52% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-8.27%
    EPS Growth Forecast (2Y CAGR)-19.52%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BCRX

    What is BCRX's market cap?

    BioCryst Pharmaceuticals has a market cap of $1.96B. Its enterprise value, which adds debt and subtracts cash, is $2.26B.

    What is BCRX's P/E ratio?

    BioCryst Pharmaceuticals has a trailing P/E ratio of 4.4x.

    How many shares of BCRX are outstanding?

    BioCryst Pharmaceuticals has 255.63M shares outstanding. The count is up 21.63% from a year earlier.

    Does BCRX pay a dividend?

    No. BioCryst Pharmaceuticals does not pay a dividend.

    How much debt does BCRX have?

    BioCryst Pharmaceuticals has $396.23M of total debt and $96.97M of cash and equivalents, a net debt position of $299.26M.